{"id":"cyclophosphamide-azathioprine-prednisone-methylprednisolone","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Bone marrow suppression/leukopenia"},{"rate":null,"effect":"Hemorrhagic cystitis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Osteoporosis"},{"rate":null,"effect":"Secondary malignancy"}]},"_chembl":{"chemblId":"CHEMBL1542","moleculeType":"Small molecule","molecularWeight":"277.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclophosphamide is an alkylating agent that cross-links DNA and preferentially depletes B and T lymphocytes. Azathioprine is a purine analog that inhibits nucleotide synthesis and lymphocyte proliferation. Corticosteroids inhibit cytokine production and immune cell activation. Together, these agents provide potent immunosuppression used in severe autoimmune and inflammatory conditions.","oneSentence":"This combination regimen suppresses the immune system through multiple pathways: cyclophosphamide and azathioprine inhibit lymphocyte proliferation, while corticosteroids (prednisone and methylprednisolone) broadly suppress inflammatory and immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:30.399Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe systemic lupus erythematosus (SLE)"},{"name":"Severe vasculitis"},{"name":"Severe autoimmune conditions refractory to conventional therapy"}]},"trialDetails":[{"nctId":"NCT04101578","phase":"","title":"Clinical Prognosis and Progression of Myasthenia Gravis Patients","status":"UNKNOWN","sponsor":"Da, Yuwei, M.D.","startDate":"2017-02-08","conditions":"Myasthenia Gravis","enrollment":2000},{"nctId":"NCT03770663","phase":"PHASE3","title":"Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-02-05","conditions":"Antisynthetase Syndrome (ASS), Interstitial Lung Disease","enrollment":76},{"nctId":"NCT03791827","phase":"","title":"Multicenter Registry of Pediatric Lupus Nephritis in China","status":"UNKNOWN","sponsor":"Xiqiang Dang","startDate":"2018-12-01","conditions":"Lupus Nephritis, Children, Steroid","enrollment":1200},{"nctId":"NCT02936375","phase":"PHASE2","title":"The Iguratimod Effect on Lupus Nephritis (IGeLU)","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-09-07","conditions":"Lupus Nephritis","enrollment":120},{"nctId":"NCT00336414","phase":"PHASE3","title":"Five-Year Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis","status":"WITHDRAWN","sponsor":"Istituto Giannina Gaslini","startDate":"2006-06","conditions":"Systemic Lupus Erythematosus Nephritis","enrollment":""},{"nctId":"NCT02294344","phase":"NA","title":"The Clinical Efficacy of DFPP in Patients With AAGN","status":"TERMINATED","sponsor":"Zhi-Hong Liu, M.D.","startDate":"2014-06","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","enrollment":14},{"nctId":"NCT00104299","phase":"PHASE2, PHASE3","title":"Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-01","conditions":"Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis","enrollment":197},{"nctId":"NCT01275287","phase":"PHASE2","title":"Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2011-05","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","enrollment":""},{"nctId":"NCT00307671","phase":"PHASE4","title":"Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-07","conditions":"Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis","enrollment":108},{"nctId":"NCT00307645","phase":"PHASE3","title":"IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2003-05","conditions":"ANCA Associated Systemic Vasculitis Including Wegener's, Granulomatosis and Microscopic Polyangiitis and, Renal Limited Vasculitis","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cyclophosphamide, Azathioprine,prednisone,methylprednisolone","genericName":"Cyclophosphamide, Azathioprine,prednisone,methylprednisolone","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen suppresses the immune system through multiple pathways: cyclophosphamide and azathioprine inhibit lymphocyte proliferation, while corticosteroids (prednisone and methylprednisolone) broadly suppress inflammatory and immune responses. Used for Severe systemic lupus erythematosus (SLE), Severe vasculitis, Severe autoimmune conditions refractory to conventional therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}